Navigation Links
Chimerix to Present at Two Upcoming Investor Conferences
Date:11/12/2009

RESEARCH TRIANGLE PARK, N.C., Nov. 12 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company advancing orally-available antiviral therapeutics to address life-threatening diseases, announced today that Kenneth I. Moch, Chief Operating Officer, will present a corporate overview at two upcoming investor conferences. Mr. Moch will discuss the company's technology assets and pipeline, including CMX001, a broad-spectrum antiviral being developed for the treatment of BK virus and cytomegalovirus in immunocompromised transplant patients and as a biodefense countermeasure in the event of a smallpox release.

Mr. Moch will speak at the Lazard Capital Markets 6th Annual Healthcare Conference on Wednesday, November 18, 2009 at 9:30 a.m. ET and at the Piper Jaffray 21st Annual Health Care Conference on Tuesday, December 1, 2009 at 9:50 a.m. ET. Both meetings are being held in New York City.

About Chimerix

Chimerix, Inc., is developing antiviral therapeutics to treat life-threatening diseases. Led by a world-class antiviral drug development team, Chimerix is advancing programs to address cytomegalovirus (CMV), BK virus, smallpox, human immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza. The company's lead compound, CMX001, is currently in Phase 1 and 2 clinical studies for the treatment of BK virus and CMV, potentially deadly infections among immunocompromised patients. CMX001 is also being evaluated for use as a biodefense countermeasure in the event of a smallpox release. Chimerix has received financing from leading venture capital firms, including Canaan Partners, Alta Partners, Sanderling Ventures, Frazier Healthcare Ventures and Asset Management Company, in addition to U.S. Government grants. Additional information about Chimerix and its antiviral drug development programs may be found online at http://www.chimerix-inc.com.

SOURCE Chimerix, Inc.


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
2. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
3. Tobira Therapeutics Announces Presentation of TBR-652 Data at European AIDS Conference
4. Trubion Announces Acceptance of Two Presentations on Its TRU-016 Product Candidate at the 2009 ASH Annual Meeting
5. Onyx Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
6. Webcast Alert: Isis Pharmaceuticals and Genzyme Corporation to Present Mipomersen Phase 3 Data in HoFH During AHA
7. Hologic to Present at NASDAQ OMX 23rd Investor Program in London
8. Accera, Inc. To Present at Lazard Capital Markets 6th Annual Healthcare Conference
9. Abaxis, Inc. to Present at the Sidoti & Company Second Annual New York Institutional Investor Forum
10. CryoLife to Present at Upcoming Investor Conferences in New York
11. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... India , March 1, 2017 ... report "Neurovascular Devices/Interventional Neurology Market by Product (Embolic ... Flow Diversion Devices, Clot Retrievers), Pathology (Aneurysm, AVM) ... this report studies the neurovascular devices/interventional neurology market ... The market is expected to reach USD 2.62 ...
(Date:3/1/2017)... Mar 01, 2017 Research and Markets has announced the addition of the ... offering. ... country level, for instance North America (U.S., Canada ... France , Italy , U.K. and Spain ... India , Australia , South Korea ...
(Date:3/1/2017)... -- ... Research and Markets has announced the addition of the ... to their offering. The Global Human Papilloma Virus ... access to partnering deals and agreements entered into by the world,s ... partnering deals. The majority of deals are discovery or development stage ...
Breaking Medicine Technology:
(Date:3/1/2017)... ... March 01, 2017 , ... Cognition Corporation ... a Human Factors Engineering (HFE) keynote speaker for its 2017 User Conference. , ... Cognition. “Human Factors is a dynamic part of product development, and our speaker ...
(Date:3/1/2017)... IL (PRWEB) , ... March 01, 2017 , ... First ... its latest funding round of $1.6 million. First Stop Health has raised total capital ... accelerate the company’s growth. , First Stop Health co-founder and CEO Patrick Spain (co-founder ...
(Date:3/1/2017)... ... March 01, 2017 , ... One of the most popular shows on ... the beloved character Toby being shocked back to life after suffering cardiac arrest on ... quickly back to his old self, ready to marry his best girl. In ...
(Date:3/1/2017)... (PRWEB) , ... March 01, 2017 , ... ... the treatment of eating disorders, is pleased to announce the opening of residential ... facility. Starting this week, Aloria Health will accept adult clients for residential treatment. ...
(Date:3/1/2017)... , ... March 01, 2017 , ... ... Lung Cancer Conference® on April 8, 2017, in Sunny Isles Beach, Florida. The ... officer, Massachusetts General Physicians Organization, Boston, and Dr. Heather Wakelee, associate professor of ...
Breaking Medicine News(10 mins):